Brazil ANVISA Medical Device Registration: The Complete Guide

Why Brazil Matters for Medical Device Companies

Brazil is the largest medical device market in Latin America and one of the largest in the world. With a population exceeding 215 million, a public healthcare system (SUS — Sistema Unico de Saude) that serves the majority of the population, and a growing private healthcare sector, Brazil represents a significant commercial opportunity for medical device manufacturers. The Brazilian medical device market has been valued at over USD 10 billion, and the country's regulatory framework has undergone substantial modernization in recent years.

But entering Brazil is not simple. The regulatory pathway is governed by ANVISA (Agencia Nacional de Vigilancia Sanitaria), and the requirements are distinct from what manufacturers are accustomed to in the US or Europe. Brazil has its own classification system, its own GMP certification process, its own in-country representative requirements, and its own technical documentation expectations. Manufacturers who treat Brazil as an afterthought — or who assume that an FDA clearance or CE mark translates directly — learn quickly that Brazil demands dedicated regulatory planning.

This guide covers every aspect of medical device registration in Brazil: ANVISA's role, risk classification, registration pathways, GMP certification via MDSAP, the Brazilian Registration Holder requirement, technical documentation, clinical evidence, fees, timelines, IVD-specific requirements, post-market obligations, and how ANVISA compares to the FDA and EU MDR frameworks.

ANVISA: The Regulatory Authority

ANVISA — Agencia Nacional de Vigilancia Sanitaria — is Brazil's national health surveillance agency, established in 1999. It is an autonomous agency linked to the Ministry of Health, responsible for protecting public health through the regulation and oversight of products and services subject to health surveillance, including pharmaceuticals, food, cosmetics, tobacco, and medical devices.

For medical devices, ANVISA's authority covers:

• Pre-market evaluation and registration of medical devices and IVDs
• Good Manufacturing Practice (GMP) inspections and certification
• Post-market surveillance including adverse event reporting, recalls, and field safety corrective actions
• Import and export control for health products
• Advertising regulation for medical devices
• Clinical trial authorization for medical devices

ANVISA operates under a legal framework established by several key pieces of legislation. The two most important resolutions for medical device manufacturers are RDC 751/2022 — the primary regulation governing medical device risk classification, notification, registration, and labeling (effective March 1, 2023, replacing the longstanding RDC 185/2001) — and RDC 830/2023 — the companion regulation governing in vitro diagnostic (IVD) medical devices (effective June 1, 2024, replacing RDC 36/2015). Together these two resolutions consolidated and modernized Brazil's medical device and IVD registration requirements. ANVISA also participates in the IMDRF (International Medical Device Regulators Forum) and is a participating authority in the MDSAP (Medical Device Single Audit Program), which has significant implications for GMP certification.

Key Regulatory Framework at a Glance

Resolution / Legislation	Scope	Effective Date
RDC 751/2022 (amended by RDC 810/2023 and RDC 848/2024)	Medical devices — classification, notification, registration, labeling, IFU	March 1, 2023
RDC 830/2023	IVD medical devices — classification, notification, registration, labeling, IFU	June 1, 2024
RDC 665/2022	Brazilian Good Manufacturing Practices (B-GMP)	2022
RDC 497/2021 (amended by RDC 850/2024)	B-GMP certification procedures and validity	2021 (amended April 1, 2024)
RDC 657/2022	Software as a Medical Device (SaMD)	July 1, 2022
RDC 741/2022	Regulatory reliance — general criteria for AREE pathway	August 10, 2022
IN 290/2024	Optimized analysis procedure leveraging AREE authorizations (medical devices)	June 3, 2024
RDC 546/2021	Adverse event reporting (tecnovigilancia)	2021
RDC 591/2021 (amended by RDC 884/2024)	Unique Device Identification (UDI)	Phased implementation
Law No. 6360/1976	General law on health surveillance	1976
Decree No. 8077/2013	Approval and monitoring of devices by ANVISA	2013

ANVISA's Organizational Structure for Medical Devices

Within ANVISA, medical device registration and oversight falls primarily under the General Management of Technology in Health Products (GGTPS). Key divisions include:

• GEMAT — General Management of Technology Products: handles registration, amendment, and renewal of medical device registrations
• GQUIP — manages GMP inspections and certification for medical device manufacturers
• GPBIO — handles post-market surveillance, vigilance, and adverse event reporting

Understanding which division handles what is important when navigating ANVISA's processes, because different submissions and inquiries are directed to different offices.

Medical Device Definition and Scope

Under Brazilian regulation, medical devices (produtos para saude) encompass a broad category that includes:

• Medical equipment (equipamentos medicos) — devices that require electrical power or a power source
• Medical materials (materiais de uso em saude) — single-use or reusable items that do not require a power source (e.g., surgical instruments, bandages, catheters)
• In vitro diagnostics (produtos para diagnostico in vitro) — reagents, instruments, and systems used for diagnostic testing outside the body

The definition is functionally similar to the FDA and EU MDR definitions: an instrument, apparatus, implement, machine, device, implant, in vitro reagent, software, material, or other similar or related article intended for use in the diagnosis, prevention, monitoring, treatment, or alleviation of disease or injury. Products that achieve their principal intended action by pharmacological, immunological, or metabolic means are excluded (those are regulated as pharmaceuticals).

What Falls Outside ANVISA Medical Device Regulation

The following are generally not regulated as medical devices by ANVISA:

• Cosmetic products (regulated separately under ANVISA's cosmetics division)
• Pharmaceutical products, including drug-device combination products where the drug is the primary mode of action
• General wellness products with no medical intended use
• Laboratory reagents for research use only (not for diagnostic purposes)
• Veterinary medical devices (regulated by the Ministry of Agriculture)

Practical tip: Drug-device combination products can be particularly complex in Brazil. If your device incorporates a medicinal substance as an integral part, ANVISA may require registration as a pharmaceutical product or may require consultation between its device and pharmaceutical divisions. Engage with ANVISA early to clarify the regulatory pathway for combination products.

Risk Classification: Classes I Through IV

Brazil uses a four-class risk-based classification system for medical devices, which aligns with the GHTF (now IMDRF) classification framework. The classes range from Class I (lowest risk) to Class IV (highest risk).

Classification Overview

Class	Risk Level	Description	Examples
Class I	Low risk	Devices that do not penetrate the body and whose failure is unlikely to result in serious harm	Tongue depressors, bandages, examination gloves, manual surgical instruments, hospital beds
Class II	Medium risk	Devices that may penetrate the body through a natural orifice or the body surface, or that contact the body for a limited duration	Hypodermic needles, surgical sutures, powered surgical instruments, blood pressure monitors, contact lenses (daily wear)
Class III	High risk	Devices that penetrate the body through surgical intervention or that are implanted for extended periods, or devices that support or sustain life	Orthopedic implants, cardiac catheters, dialysis equipment, ventilators, infusion pumps, intraocular lenses
Class IV	Very high risk	Devices that are implanted in direct contact with the heart, central nervous system, or central circulatory system, or that incorporate biological materials or medicinal substances	Cardiovascular stents, pacemakers, heart valves, defibrillators, spinal cord stimulators, devices incorporating drug components

Classification Rules

Under RDC 751/2022, Brazil's classification rules have been expanded from 18 to 22 rules (Annex I of RDC 751/2022), adopted from the EU MDR Annex VIII classification rules. This alignment means that manufacturers familiar with EU MDR classification can apply similar logic for Brazil. The classification rules consider the following factors:

• Duration of contact — transient (less than 60 minutes), short-term (up to 30 days), or long-term (more than 30 days)
• Invasiveness — non-invasive, invasive through a body orifice, or surgically invasive
• Active vs. non-active — whether the device relies on a power source
• Intended purpose — diagnostic, therapeutic, monitoring
• Body system contacted — central circulatory system, central nervous system, etc.
• Special considerations — incorporation of medicinal substances, biological materials, nanomaterials (new under RDC 751/2022), or Software as a Medical Device (SaMD, classified independently when standalone)

The 22 rules are grouped into categories:

• Rules 1–4: Non-invasive devices
• Rules 5–8: Invasive devices (body orifice and surgically invasive)
• Rules 9–13: Active devices (therapeutic, diagnostic, and monitoring)
• Rules 14–22: Special rules (devices with medicinal substances, contraceptives, disinfectants for invasive devices, nanomaterials, devices consisting of substances, etc.)

When multiple rules apply to a device, the most stringent rule prevails (highest risk class applies).

ANVISA vs. FDA vs. EU MDR Classification Comparison

ANVISA (Brazil)	FDA (US)	EU MDR (Europe)	Risk Level
Class I	Class I (exempt/510(k))	Class I	Lowest
Class II	Class II (510(k))	Class IIa	Low-medium
Class III	Class II (510(k)) / Class III (De Novo/PMA)	Class IIb	Medium-high
Class IV	Class III (PMA)	Class III	Highest

Important: These are rough equivalences, not exact mappings. A device classified as Class II in Brazil is not necessarily Class II in the US. The classification rules differ, and you must determine classification independently for each market. ANVISA provides a classification database and can also issue formal classification opinions upon request.

How to Determine Your Device Classification

Manufacturers can determine classification through several routes:

1. ANVISA's product classification database — search by device type or generic name to find existing classifications
2. Classification rules — apply the 18 classification rules to your device based on its intended use, invasiveness, duration of contact, and other factors
3. Formal classification request — submit a request to ANVISA for a formal classification determination if the classification is unclear
4. Comparison with similar registered products — review how comparable devices already registered in Brazil are classified

Getting classification right is the foundation of your Brazilian regulatory strategy. Classification determines whether your device goes through the simplified Cadastro pathway or the full Registro pathway, and it directly affects your timeline, documentation burden, and fees.

Registration Pathways: Cadastro vs. Registro

Brazil has two primary pathways for bringing a medical device to market: Cadastro (notification) and Registro (registration). The pathway depends on the device's risk classification.

Cadastro (Notification) — Classes I and II

Cadastro is a simplified notification pathway for lower-risk devices (Classes I and II). The term translates roughly as "registration" but functions more like a notification or listing — it is faster and less burdensome than the full Registro pathway.

Key characteristics of Cadastro:

• Applies to Class I and Class II medical devices
• ANVISA performs an administrative review (document completeness check) rather than a full technical assessment
• Typical timeline: 30 to 90 days from submission
• Valid for 10 years (renewed upon expiration)
• Lower fees compared to Registro
• Technical documentation must still be prepared and maintained but is not routinely reviewed by ANVISA during the notification process (it can be requested at any time)

What you submit for Cadastro:

• Application form (via ANVISA's Solicita portal — the electronic submission system that digitizes all petitions, auto-generates the GRU fee payment slip, and timestamps applications. All submissions are now fully electronic.)
• Proof of the BRH (Brazilian Registration Holder) appointment
• Device identification and description
• Intended use statement
• Risk classification justification
• Labeling in Portuguese (including Instructions for Use)
• GMP certificate — either a BGMP certificate issued by ANVISA or an MDSAP certificate
• Letter of authorization from the manufacturer to the BRH
• Applicable INMETRO certifications (for electromedical equipment)
• Payment of applicable fees

Registro (Registration) — Classes III and IV

Registro is the full registration pathway for higher-risk devices (Classes III and IV). This pathway involves a substantive technical review by ANVISA — they examine the technical documentation, clinical evidence, and risk analysis in detail before granting marketing authorization.

Key characteristics of Registro:

• Applies to Class III and Class IV medical devices
• ANVISA performs a thorough technical assessment of the entire dossier
• Typical timeline: 9 to 18 months (can exceed 24 months for complex devices)
• Valid for 10 years (renewed upon expiration)
• Higher fees
• Complete technical documentation must be submitted and reviewed
• Clinical evidence requirements are more stringent

What you submit for Registro:

• All items required for Cadastro (above), plus:
• Complete technical dossier (design description, materials, specifications, manufacturing process summary)
• Risk analysis per ISO 14971
• Preclinical testing reports (biocompatibility, electrical safety, performance testing, sterilization validation, etc.)
• Clinical evidence (clinical investigation data, clinical evaluation, literature review)
• Software documentation (for devices with software — IEC 62304 lifecycle documentation and cybersecurity information)
• Stability and shelf-life data (where applicable)
• Summary of safety and clinical performance
• Comparison with existing similar products on the market

Cadastro vs. Registro: Summary

Feature	Cadastro (Classes I & II)	Registro (Classes III & IV)
Risk class	Class I, Class II	Class III, Class IV
Review type	Administrative (document completeness)	Substantive technical review
Technical dossier review	Not routinely reviewed at submission; maintained on file	Fully reviewed by ANVISA
Clinical evidence	Generally not required at submission	Required — scope depends on device type and class
Typical timeline	30–90 days	9–18 months
Validity	10 years	10 years
Fee level	Lower	Higher
GMP certificate required	Yes	Yes
BRH required	Yes	Yes

Petition for Accelerated Review

ANVISA provides priority review pathways for certain categories of devices:

• Innovative devices — devices that represent a significant technological advance for an unmet medical need in Brazil
• Public health emergencies — devices needed to address declared public health emergencies
• Pediatric devices — devices designed specifically for pediatric populations
• Rare disease devices — devices intended for the diagnosis or treatment of rare diseases

Priority review does not change the substantive requirements — it moves the application to the front of ANVISA's review queue. Manufacturers must apply for priority status with supporting justification.

Brazilian Good Manufacturing Practice (B-GMP) and MDSAP

One of the most critical prerequisites for any medical device registration in Brazil — whether Cadastro or Registro — is a valid Good Manufacturing Practice (GMP) certificate. Without it, your registration application will not be accepted. This requirement applies to all manufacturers, both domestic and foreign.

The GMP Certificate Requirement

Brazil requires that every manufacturer of a registered medical device holds a certificate of Good Manufacturing Practice (Certificado de Boas Praticas de Fabricacao — CBPF). Historically, this meant that ANVISA inspectors would travel to the manufacturer's facility — including international facilities — to conduct an on-site GMP inspection. For foreign manufacturers, this created significant delays:

• ANVISA had limited inspector capacity for international inspections
• Travel logistics, visa processing, and scheduling added months to the timeline
• Wait times for an ANVISA GMP inspection could be 12 to 24 months or more
• The CBPF was valid for only 2 years, requiring reinspection

MDSAP as an Alternative to ANVISA GMP Inspection

The game-changer for foreign manufacturers was ANVISA's participation in the MDSAP program. Since 2017, ANVISA has accepted MDSAP audit reports as evidence of GMP compliance, which can replace the traditional on-site ANVISA GMP inspection for foreign manufacturers.

Here is how it works:

1. The manufacturer undergoes an MDSAP audit conducted by a recognized Auditing Organization (AO) that includes Brazil in its scope
2. The MDSAP audit covers ISO 13485 as the baseline QMS plus Brazilian regulatory requirements (ANVISA-specific clauses)
3. The resulting MDSAP certificate and audit report serve as evidence of GMP compliance
4. The manufacturer (through the BRH) submits the MDSAP certificate to ANVISA as part of the device registration application
5. ANVISA accepts this in lieu of sending its own inspectors

This is a critical path item. For most foreign manufacturers, obtaining an MDSAP certificate with Brazil included in the scope is by far the fastest and most practical way to satisfy ANVISA's GMP requirement. The alternative — waiting for ANVISA to schedule and conduct an on-site international inspection — can add a year or more to your market entry timeline.

MDSAP Requirements Specific to Brazil

When your MDSAP audit includes Brazil in scope, the auditing organization must verify compliance with ANVISA-specific requirements in addition to ISO 13485. These include:

• Complaint handling and adverse event reporting — ANVISA requires specific reporting timelines and formats for adverse events (tecnovigilancia)
• Post-market surveillance — ANVISA expects active monitoring of device performance in the market
• Traceability requirements — particularly for implantable devices, ANVISA has specific traceability requirements
• Labeling in Portuguese — the MDSAP auditor will verify that labeling controls include provisions for Portuguese-language labeling as required by Brazilian regulations
• Product registration maintenance — ANVISA expects manufacturers to maintain and update their registrations

Practical tip: When selecting your MDSAP Auditing Organization, confirm that they have auditors with specific experience in ANVISA requirements. Not all MDSAP AOs have equal depth of expertise across all five participating countries. Ask for references from companies that have successfully used their MDSAP certificate for ANVISA registration.

B-GMP Certificate Validity, Renewal, and the RDC 850/2024 Extension

A major development occurred on March 20, 2024, when ANVISA published Resolution RDC 850/2024, amending Article 8 of RDC 497/2021. This resolution officially extended the B-GMP certificate validity from two years to four years for manufacturers who hold an MDSAP certificate that includes Brazil in its scope. The extension took effect on April 1, 2024.

Certificate Type	Validity	Renewal Process	Key Condition
ANVISA CBPF (direct inspection, no MDSAP)	2 years	Re-inspection by ANVISA inspectors	N/A
ANVISA CBPF with MDSAP certificate	4 years (per RDC 850/2024)	MDSAP recertification; B-GMP renewal via BRH	MDSAP certificate must remain current for the full B-GMP period
MDSAP certificate itself	3 years (with annual surveillance)	MDSAP recertification audit	Must include Brazil in scope

Important details about the B-GMP extension:

• The 4-year validity applies only to new certificates and renewals issued after April 1, 2024. B-GMP certificates already issued with a 2-year validity retain their original expiration date until their next renewal.
• If the manufacturer's MDSAP certificate lapses during the B-GMP period, the B-GMP certificate may also be jeopardized.
• Manufacturers who had submitted a B-GMP renewal petition before April 1, 2024 but had not yet received final approval can still benefit from the 4-year extension.
• The B-GMP fee for international manufacturers is BRL 72,804.90 (approximately USD 13,500) per manufacturer. This fee applies per certification cycle regardless of whether the validity is 2 or 4 years, making MDSAP participation significantly more cost-effective.
• Manufacturers located in Mercosur member countries qualify for a reduced B-GMP fee of BRL 10,637 (approximately USD 1,980).

The MDSAP certificate's 3-year cycle (with annual surveillance audits) aligns well with ANVISA's expectations. However, manufacturers must ensure their MDSAP certificate remains current — a lapsed certificate can jeopardize existing registrations.

MDSAP Auditing Organizations Recognized by ANVISA

Not all MDSAP Auditing Organizations (AOs) have equal depth of expertise across all five participating countries. The following AOs are recognized by ANVISA to conduct MDSAP audits with Brazil in scope:

• BSI
• CSA Group
• DEKRA Certification
• Intertek / Semko
• LRQA (formerly Lloyd's Register)
• Prestige Certification (formerly Registrar Corp)
• SGS
• TUV Nord
• TUV Rheinland
• TUV SUD

Practical tip: When your MDSAP certificate includes Brazil, ANVISA uses a risk-based approach (per RDC 687/2022, Article 8) to determine whether the manufacturer will be subject to an on-site inspection or a desktop audit. For most manufacturers with a clean MDSAP audit history, ANVISA will issue the B-GMP certificate based on a desktop review of the MDSAP report — no ANVISA inspector visit required. This typically takes approximately 2 months from petition submission to B-GMP certificate issuance.

INMETRO Certification

INMETRO (Instituto Nacional de Metrologia, Qualidade e Tecnologia) is Brazil's national metrology, quality, and technology institute. For certain categories of medical devices — specifically electromedical equipment — INMETRO certification is mandatory in addition to ANVISA registration.

When INMETRO Certification Is Required

INMETRO certification is required for medical equipment that falls under the scope of Brazil's conformity assessment programs. The scope is broader than many manufacturers realize — it is not limited to electromedical equipment. Products requiring INMETRO certification include:

Electromedical equipment (Portaria INMETRO 384/2020):

• Equipment powered by electrical mains or batteries
• Equipment covered by the IEC 60601 series of standards
• Examples: patient monitors, infusion pumps, surgical equipment, diagnostic imaging systems, defibrillators, ventilators, electrosurgical units, laser systems, ultrasound devices

Non-electrical medical devices also requiring INMETRO certification:

• Hypodermic needles and syringes
• Condoms and other barrier contraceptives
• Medical gloves (surgical and examination)
• Breast implants
• Mechanical wheelchairs
• Dental handpieces
• Infusion sets
• Mattresses for medical use

Important distinction: For non-electrical products (needles, condoms, gloves, etc.), in-country testing in Brazil is required — test reports from international labs are generally not accepted for these categories. For electromedical devices, testing can typically be done outside Brazil at an ILAC-accredited laboratory.

The INMETRO Certification Process

INMETRO certification follows Model 5 conformity assessment, which includes product testing, documentation review, and manufacturing site assessment:

1. Identify the applicable INMETRO regulation — determine which Portaria (ordinance) covers your product category. The primary regulation is Portaria INMETRO 384/2020, which governs the conformity assessment of electromedical equipment. The applicable technical standards are listed in Normative Instruction IN 116/2021 (ANVISA), which is currently under revision.
2. Appoint a local representative — foreign manufacturers cannot apply directly for INMETRO certification. A Brazilian company (typically your BRH) must liaise with the certification body on your behalf.
3. Select an accredited certification body (OCP — Organismo de Certificacao de Produto) — INMETRO-accredited bodies conduct the conformity assessment. Major OCPs include TUV Rheinland, UL Solutions, Intertek, and Brazilian bodies such as BRTÜV and CEPEL.
4. Submit documentation — technical file, test reports to applicable standards
5. Product testing — for electromedical equipment, testing must comply with IEC 60601-1 Edition 3.1 (mandated by RDC 549/2021 and Instruction IN-283/2024) and applicable collateral and particular standards. Testing can be performed at an ILAC-accredited laboratory outside Brazil or at a Brazilian accredited laboratory. The OCP validates the test reports.
6. Factory audit — the OCP conducts a manufacturing site audit as part of the initial certification
7. Certificate issuance — upon successful assessment, the OCP issues a conformity certificate
8. INMETRO mark — certified products must bear the INMETRO mark on labeling

INMETRO Certificate Validity and Maintenance

Under Portaria INMETRO 384/2020, INMETRO certificates for electromedical equipment have indefinite validity — they do not expire. However, certification must be maintained through:

• Annual surveillance audits — the OCP conducts periodic audits to verify continued compliance
• Updated test reports — if ANVISA revises the applicable standards listed in IN 116/2021, the OCP will immediately request updated test reports for the new standards. Failure to provide them can result in cancellation of both the INMETRO certificate and the ANVISA registration.
• Change notifications — any design changes that affect safety or performance must be reported to the OCP

Cost and timeline: Initial INMETRO certification typically costs USD 4,000 to USD 6,000 for electromedical devices (excluding any additional testing costs) and takes approximately 90 days to 6 months depending on device complexity and documentation readiness. Ongoing annual maintenance costs are approximately USD 1,000 per certificate.

INMETRO and ANVISA: The Relationship

INMETRO certification and ANVISA registration are separate but complementary requirements. You need both for electromedical devices:

• INMETRO certifies that the product meets the applicable safety and performance standards (primarily IEC 60601-series)
• ANVISA registers the device for commercial distribution and evaluates the broader regulatory dossier

You should initiate the INMETRO certification process in parallel with your ANVISA registration — not sequentially. Both processes take time, and the INMETRO certificate is typically a prerequisite for completing the ANVISA registration for electromedical products.

Practical tip: If you have IEC 60601 test reports from an internationally recognized test laboratory (such as a lab accredited by an ILAC-MRA signatory), these reports may be accepted by the INMETRO-accredited certification body, avoiding the need for retesting. Confirm acceptance before assuming your existing test reports will suffice.

ANATEL Certification for Wireless Medical Devices

In addition to INMETRO, medical devices that incorporate wireless communication capabilities require certification from ANATEL (Agencia Nacional de Telecomunicacoes) — Brazil's national telecommunications agency. This is a requirement that catches many foreign manufacturers off guard.

When ANATEL Certification Is Required

ANATEL certification (formally called "homologation") is mandatory for any device that transmits or receives radio frequency (RF) signals, including:

• Bluetooth — patient monitors, wearable sensors, hearing aids with Bluetooth connectivity
• Wi-Fi — connected diagnostic equipment, telemedicine devices, smart infusion pumps
• RFID — surgical instrument tracking systems, asset management devices
• Cellular / LTE / 5G — remote patient monitoring devices, connected implantables
• Zigbee, LoRa, NB-IoT — hospital sensor networks, environmental monitoring

ANATEL Certification Process

ANATEL categorizes products into three categories with different testing and renewal requirements:

Category	Description	Testing Requirement	Certification Maintenance
Category I	Products transmitting RF intentionally (mobile devices, base stations)	Full laboratory testing	Annual re-evaluation with lab testing
Category II	Products using RF on a secondary basis (Bluetooth, Wi-Fi modules)	Laboratory testing	Bi-annual re-evaluation (documentation only)
Category III	Products that receive but do not transmit RF, or are wired telecom	Documentation review	Periodic documentation review

Most wireless medical devices fall into Category I or II.

The certification process follows these steps:

1. Register in ANATEL's SGCH (Mosaico) system — the applicant must be a Brazilian legal entity with a valid CNPJ. Foreign manufacturers must work through their BRH or a local representative.
2. Select a Designated Certification Body (OCD) — an ANATEL-accredited body that manages the certification process
3. Laboratory testing — RF performance, electromagnetic compatibility (EMC), electrical safety, and SAR (Specific Absorption Rate) testing as applicable. Testing is typically conducted at accredited laboratories in Brazil, though some international test results may be accepted.
4. OCD review and certificate issuance — the OCD reviews test reports and issues a Certificate of Conformity
5. ANATEL homologation — the OCD submits the certificate to ANATEL via the SGCH system. Upon approval, the device receives a unique ANATEL homologation ID that must appear on the product.

Key Considerations for ANATEL

• Cost: Approximately USD 3,000 to USD 4,000 per device
• Timeline: Approximately 3 months from start to finish
• Non-transferable: Each importer must obtain its own ANATEL certification, even if the manufacturer has certified the product in other regions
• Device must typically be sent to Brazil for testing
• Independent of ANVISA and INMETRO — ANATEL certification is a separate requirement. You may need all three (ANATEL + INMETRO + ANVISA registration) for a wireless electromedical device.
• Starting in 2025, new ANATEL regulations introduce stricter rules for mobile and IoT devices, including requirements for 5G NB-NTN and RedCap technologies.

Practical tip: ANATEL certification should be initiated in parallel with INMETRO certification and ANVISA registration preparation. The ANATEL homologation ID is a prerequisite document for the ANVISA submission. Delays in ANATEL testing can hold up your entire registration timeline.

Brazilian Registration Holder (BRH)

Foreign manufacturers cannot register medical devices directly with ANVISA. Brazilian law requires that a local entity — the Brazilian Registration Holder (BRH), sometimes called the legal representative or in-country representative — hold the registration on behalf of the foreign manufacturer. This is analogous to the Authorized Representative requirement under EU MDR or the US Agent requirement for FDA establishment registration, though the BRH's role and responsibilities are more extensive.

BRH Requirements

The BRH must be:

• A legal entity established and registered in Brazil (holding a valid CNPJ — Cadastro Nacional da Pessoa Juridica)
• Registered with ANVISA as a medical device company (holding an AFE — Autorizacao de Funcionamento de Empresa, which is ANVISA's operating authorization)
• Licensed by the local health surveillance authority (Vigilancia Sanitaria) in the state and municipality where it is located (Alvara Sanitario)
• Staffed with a qualified technical director (Responsavel Tecnico) — typically a professional with a background in engineering, pharmacy, biomedicine, or a related health science

Understanding the AFE (Autorizacao de Funcionamento de Empresa)

The AFE is the fundamental operating authorization issued by ANVISA that permits a company to conduct regulated activities with medical devices in Brazil. The AFE specifies which activities the company is authorized to perform — these may include importing, distributing, storing, manufacturing, exporting, and/or commercializing medical devices. The BRH's AFE must explicitly include import activities if the BRH will be importing products on behalf of the foreign manufacturer.

The AFE application is submitted through ANVISA's electronic system and requires demonstration of adequate physical facilities, qualified personnel, and compliance with applicable sanitary requirements. The AFE must be maintained current — ANVISA can suspend or cancel it for non-compliance.

Understanding the Alvara Sanitario

In addition to the federal-level AFE, the BRH must hold a state and/or municipal sanitary license (Alvara Sanitario) issued by the local Vigilancia Sanitaria authority. This license confirms that the BRH's physical facilities comply with local sanitary regulations. Requirements vary by state and municipality, and obtaining the Alvara involves a facility inspection by local health authorities.

The Responsavel Tecnico (Technical Director)

Brazilian law requires every medical device company (including BRHs) to have a designated Responsavel Tecnico — a technically qualified individual who is legally responsible for the technical aspects of the company's operations. This person must:

• Hold a relevant university degree (typically in pharmacy, engineering, biomedicine, or a health-related field)
• Be registered with the relevant professional council (e.g., CRF for pharmacists, CREA for engineers)
• Be physically present and available at the company's registered address
• Sign off on regulatory submissions, technical documents, and adverse event reports

Practical tip: When evaluating a potential BRH, verify not only that they hold a valid AFE and Alvara Sanitario, but also that the AFE explicitly covers the activities you need (import, distribution, storage). Also confirm that their Responsavel Tecnico has specific experience with medical device regulations — not just pharmaceutical expertise. A BRH whose technical director lacks medical device experience may struggle with ANVISA's device-specific requirements.

BRH Responsibilities

The BRH is not a passive address for correspondence. Under Brazilian law, the BRH assumes substantial legal responsibility:

• Registration holder — the registration is issued in the BRH's name, and the BRH is legally responsible for the product in Brazil
• Adverse event reporting — the BRH must report adverse events and complaints to ANVISA within the required timelines
• Post-market surveillance — the BRH must conduct post-market surveillance activities and maintain complaint records
• Labeling compliance — the BRH must ensure all labeling is in Portuguese and complies with ANVISA requirements
• Import management and Letters of Importation — the BRH handles import documentation and customs clearance for medical devices. Under RDC 81/2008, the BRH issues Cartas de Importacao (Letters of Importation) — notarized authorization letters that permit distributors to import the registered products. Each shipment typically requires a Letter of Importation referencing the ANVISA registration number. The BRH can authorize multiple distributors to import on the manufacturer's behalf.
• Regulatory correspondence — all communications with ANVISA go through the BRH
• Record retention — the BRH must maintain registration files and technical documentation accessible to ANVISA
• Field safety actions — the BRH must execute recalls, field safety corrective actions, and safety notices in Brazil

Choosing a BRH

Foreign manufacturers typically use one of two approaches:

1. Third-party regulatory agent — a specialized regulatory services company that acts as the BRH for multiple foreign manufacturers. This is the most common approach for companies entering Brazil without a local subsidiary. Pros: established infrastructure, regulatory expertise, existing ANVISA relationships. Cons: you do not control the BRH directly, and the registration is held in their name.

2. Own subsidiary — establishing a Brazilian legal entity (subsidiary or branch office) that serves as the BRH. Pros: direct control, the registration is in your own entity's name, strategic for long-term market commitment. Cons: significant investment in legal setup, tax registration, hiring, ongoing compliance with Brazilian corporate and tax law.

Critical consideration: If your registration is held by a third-party BRH and you decide to change BRH providers, the registration must be transferred to the new entity. This process requires ANVISA approval and can take several months. During the transfer, your ability to import and sell may be disrupted. Choose your BRH carefully and negotiate contracts that protect your interests, including clear provisions for registration ownership, transfer rights, and transition assistance.

BRH vs. Similar Roles in Other Markets

Role	Market	Holds Registration?	Legal Liability?	Adverse Event Reporting?
BRH	Brazil (ANVISA)	Yes — registration in BRH's name	Yes — full legal responsibility	Yes — primary reporting obligation
Authorized Representative	EU (MDR)	No — certificate in manufacturer's name	Yes — shared liability under MDR	Yes — supports manufacturer's reporting
US Agent	US (FDA)	No — establishment registered by manufacturer	Limited — communication conduit	No — manufacturer reports directly
MAH (Marketing Authorization Holder)	Japan (PMDA)	Yes — registration in MAH's name	Yes — legal responsibility	Yes — primary reporting obligation

Clinical Evidence Requirements

ANVISA's clinical evidence requirements depend on the device's risk class and how novel the device is. Brazil follows a clinical evidence framework that shares conceptual alignment with the EU MDR approach — requiring a proportionate body of clinical evidence based on risk — but with its own specific requirements.

Clinical Evidence by Risk Class

Risk Class	Clinical Evidence Requirement
Class I	Generally not required. A clinical evaluation based on literature may suffice if specific claims are made.
Class II	Clinical evaluation based on literature review and equivalence to existing devices. Clinical investigation data generally not required unless the device is novel or makes novel claims.
Class III	Clinical evaluation required, including literature review and, for many device types, clinical investigation data. ANVISA expects robust evidence of safety and performance.
Class IV	Full clinical evaluation and typically clinical investigation data required. For devices in direct contact with the heart, CNS, or central circulatory system, the clinical evidence expectations are the highest.

Clinical Investigations in Brazil

If your device requires a clinical investigation conducted in Brazil, you must obtain ANVISA approval before beginning the study. The process involves:

1. Ethics Committee (CEP) approval — all clinical investigations must be reviewed and approved by an institutional Research Ethics Committee (Comite de Etica em Pesquisa)
2. CONEP approval — for certain categories of research (including international multicenter studies), the National Research Ethics Commission (CONEP) must also approve
3. ANVISA clinical trial authorization — submit the clinical investigation application to ANVISA, including the protocol, investigator's brochure, informed consent forms, and ethics committee approvals
4. ClinicalTrials.gov and REBEC registration — the study must be registered in the Brazilian Clinical Trials Registry (REBEC — Registro Brasileiro de Ensaios Clinicos)

Acceptance of Foreign Clinical Data

ANVISA generally accepts clinical data generated outside Brazil, provided:

• The clinical investigation was conducted in accordance with applicable international standards (ISO 14155 for medical devices)
• The data is from a population and clinical setting reasonably representative of the Brazilian context
• The study was conducted under appropriate ethical oversight (GCP compliance)
• The data is complete and available for ANVISA review

However, ANVISA may request additional data or a bridging study if there are concerns about the applicability of foreign data to the Brazilian population — for example, if the device's performance could be affected by genetic, environmental, or healthcare system differences.

Practical tip: If you have clinical data from your FDA or EU MDR submissions, that data is typically the starting point for your Brazilian dossier. However, do not assume ANVISA will accept it without question. Prepare a clinical evaluation that addresses the relevance of your data to the Brazilian market, and be prepared to supplement with additional literature or data if ANVISA raises questions.

Technical Documentation Requirements

ANVISA's technical documentation requirements are comprehensive and largely aligned with international standards (IMDRF STED — Summary Technical Documentation). The documentation must be prepared in Portuguese or, in some cases, submitted in English with a Portuguese summary. ANVISA may request full Portuguese translations of any document.

Core Technical Documentation Components

Document	Description	Required For
Device description	Detailed description of the device, including materials, components, accessories, variants, sizes, and how it works	All classes
Intended use / indications for use	Clear statement of what the device is intended to do and the patient population	All classes
Risk analysis	Risk management per ISO 14971, including risk analysis, risk evaluation, risk control, and residual risk assessment	All classes
Design and manufacturing information	Description of the design process, manufacturing process, quality controls, and specifications	Classes III and IV (summary for I and II)
Preclinical testing	Biocompatibility (ISO 10993), electrical safety (IEC 60601), performance testing, sterilization validation, packaging validation, stability/shelf-life	Class-dependent
Clinical evidence	Clinical evaluation report, clinical investigation data, literature review	Classes III and IV primarily
Software documentation	IEC 62304 software lifecycle documentation, software description, cybersecurity documentation	All classes with software
Labeling	Proposed labels, IFU, and packaging — all in Portuguese	All classes
Sterilization information	Sterilization method, validation, residuals testing	All sterile devices
Biocompatibility	ISO 10993 biological evaluation, testing reports	All devices with body contact

Labeling Requirements

Brazilian labeling requirements are detailed and strictly enforced. All labeling — including the device label, Instructions for Use (IFU), and packaging — must be in Portuguese (Brazilian Portuguese). Key requirements include:

• Product name — in Portuguese
• Manufacturer name and address
• BRH name and address — must appear on the label
• ANVISA registration number — must appear on the commercial packaging
• Lot/batch number and serial number (where applicable)
• Manufacturing date and expiration date (where applicable)
• Storage conditions
• "PRODUTO PARA SAUDE" designation (or equivalent)
• Sterilization method (for sterile devices)
• Single-use designation ("USO UNICO") where applicable
• Warnings and precautions — in Portuguese
• Instructions for Use — comprehensive IFU in Portuguese
• UDI — as applicable under ANVISA's UDI implementation timeline
• INMETRO mark — for electromedical equipment subject to INMETRO certification

Practical tip: Do not underestimate the labeling workload for Brazil. Portuguese translations must be accurate, and ANVISA reviewers will scrutinize labeling during their assessment. Use professional medical translators with experience in Brazilian Portuguese (not European Portuguese — there are meaningful differences in medical terminology). Errors in labeling are one of the most common reasons for ANVISA deficiency letters.

ANVISA Fees and Timeline

Fee Structure

ANVISA charges fees for registration, renewal, amendments, and other regulatory actions. Fees are published annually in ANVISA's resolution on health surveillance fees (Taxa de Fiscalizacao de Vigilancia Sanitaria — TFVS). Fees are assessed in Brazilian Reais (BRL) and are subject to annual adjustment. The TFVS payment is also required for import clearance — it is being integrated into the Single Foreign Trade Portal (SISCOMEX/PCCE) to streamline payment alongside customs duties.

ANVISA Government Fees (Current Schedule)

Regulatory Action	Fee (BRL)	Approximate Fee (USD)*
Notificacao (Classes I/II) — per product	R$ 1,406	~$262
Registro (Classes III/IV) — standard device family	R$ 8,510	~$1,584
Registro (Classes III/IV) — large device family	R$ 19,856	~$3,696
B-GMP certification — international manufacturer	R$ 72,804.90	~$13,500
B-GMP certification — Mercosur manufacturer	R$ 10,637	~$1,980
Procedural review fee (if applicable)	R$ 1,406	~$262
Registration renewal (10-year)	R$ 2,000 – R$ 15,000	$400 – $3,000
Registration amendment	R$ 1,000 – R$ 10,000	$200 – $2,000
Classification opinion	R$ 1,000 – R$ 3,000	$200 – $600

*USD equivalents are approximate based on exchange rate of ~BRL 5.38/USD. Exchange rate fluctuation can significantly affect costs. ANVISA adjusts fees periodically — always verify current fees before submission.

Total Cost of Registration (Including Third-Party Costs)

Government fees are only one component. The total cost of ANVISA registration typically includes:

Cost Component	Class I/II	Class III/IV
ANVISA government fee	~R$ 1,406 per product	R$ 8,510 – R$ 19,856 per product
B-GMP certification (ANVISA fee)	Not required for Class I/II	R$ 72,804.90 per manufacturer
BRH annual representation fee	USD 1,000 – 2,000/year per product	USD 1,500 – 3,000/year per product
Dossier preparation and submission	USD 1,000 – 2,000 per product	USD 4,000 – 6,000 per product
INMETRO certification (if applicable)	USD 4,000 – 6,000	USD 4,000 – 6,000
ANATEL certification (if applicable)	USD 3,000 – 4,000	USD 3,000 – 4,000
Portuguese translations	USD 2,000 – 5,000	USD 5,000 – 15,000+
Total estimated range	USD 5,000 – 15,000	USD 25,000 – 60,000+

Note: B-GMP certification is a per-manufacturer cost, not per-product. A manufacturer with 10 Class III/IV registrations pays the B-GMP fee once (R$ 72,804.90), not 10 times. This makes portfolio expansion significantly more cost-effective after the initial B-GMP investment. The B-GMP renewal fee is the same amount, payable every 2 years (or every 4 years if the manufacturer holds an MDSAP certificate, per RDC 850/2024).

Timeline Expectations

Timelines for ANVISA registration vary significantly based on risk class, the completeness of the submission, and ANVISA's current workload.

Pathway	Best Case	Typical	Worst Case
Cadastro (Classes I/II)	30 days	60–90 days	6 months (if deficiencies)
Registro (Class III)	6 months	12–15 months	24+ months
Registro (Class IV)	9 months	15–18 months	30+ months
Registro (Class III/IV) via AREE reliance pathway	3 months	6–9 months	12 months
B-GMP certificate via MDSAP	1 month	2 months	4 months
B-GMP certificate via ANVISA inspection	6 months	12–18 months	24+ months
INMETRO certification	3 months	6–9 months	12+ months
ANATEL certification	2 months	3 months	6 months

Critical path considerations:

• The GMP certificate is the most common bottleneck. Without it, ANVISA will not process your registration. If you do not have an MDSAP certificate with Brazil in scope, start the process immediately.
• ANVISA issues deficiency letters (exigencias) during the review. You typically have a defined period (often 60 to 90 days) to respond. Incomplete or inadequate responses reset the review clock and can add months.
• Total time from decision to enter Brazil to first commercial sale is typically 18 to 30 months for Class III/IV devices, accounting for GMP certification, registration, and import logistics.

RDC 751/2022, RDC 830/2023, and Recent Regulatory Reforms

Brazil's regulatory framework for medical devices underwent its most significant modernization in two decades with the publication of two landmark resolutions:

RDC 751/2022 — The Medical Device Regulation

RDC 751/2022 (effective March 1, 2023) is the primary regulation for medical devices (excluding IVDs). It replaced the longstanding RDC 185/2001 and consolidated medical device risk classification, registration procedures, and labeling requirements into a single resolution. Key features of RDC 751/2022 include:

• 22 classification rules (expanded from 18 under the previous framework), adopted from the EU MDR Annex VIII. This means Brazil's classification rules are now closely aligned with European MDR rules, enabling manufacturers familiar with EU MDR classification to apply similar logic for Brazil.
• SaMD and nanomaterial provisions — specific classification rules for Software as a Medical Device (SaMD) and devices incorporating nanomaterials
• Structured change management — three categories of post-market changes: (1) changes requiring ANVISA approval before implementation, (2) changes that can be implemented immediately upon filing, and (3) non-reportable changes. This provides clearer guidance compared to the prior ad hoc approach.
• STED-aligned technical documentation — technical dossier requirements structured per the IMDRF Table of Contents (nlVD MA ToC)
• Indefinite validity for Class I/II notifications — Notificacoes for Class I and II devices do not expire (though they can be cancelled for non-compliance). Class III/IV Registros remain valid for 10 years with renewal.
• Incorporation of Mercosur Resolution GMC No. 25/2021 — harmonizing classification and documentary requirements with other Mercosur member states
• SBAC requirements — formalizes that certain devices require compliance certification by INMETRO and/or ANATEL under the Brazilian Conformity Assessment System (SBAC)

RDC 751/2022 has been amended by RDC 810/2023 and supplemented by RDC 848/2024 (which introduced the Essential Safety and Performance Requirements Checklist).

RDC 830/2023 — The IVD Regulation

RDC 830/2023 (effective June 1, 2024) is the companion regulation specifically for in vitro diagnostic (IVD) medical devices. It replaced RDC 36/2015 and aligned IVD regulation with the administrative framework established by RDC 751/2022 for devices. Key features include:

Area	Previous Framework (RDC 36/2015)	RDC 830/2023
IVD classification	Based on older ANVISA rules	Updated classification aligned with IMDRF/IVD WG/N64FINAL:2021, using Classes A through D (mapping to Brazil's Classes I–IV)
Classification rules	Limited rules	8 classification rules covering blood screening, blood grouping, infectious agents, self-tests, general reagents, and controls
Technical documentation	Multiple formats	Consolidated, STED-aligned documentation requirements
Electronic submissions	Partial	Full electronic submission via ANVISA's Solicita system
Labeling	Separate requirements	Consolidated labeling requirements; e-labeling permitted for some products (prohibited for self-tests and lay-user devices)
Documentary repository	Not required	IFU must be uploaded to ANVISA's digital repository within 30 days of publication
Language	Portuguese required	Documents (except labeling and ANVISA forms) can be submitted in English, Spanish, or Portuguese
Mercosur alignment	Limited	Related to Mercosur Resolution GMC 24/21

Key IVD classification changes under RDC 830/2023:

• Some IVDs were reclassified (up-classified or down-classified). Devices that changed from notification to registration (or vice versa) had until June 1, 2025 to submit reclassification applications.
• Labeling had to be adapted within 120 days of June 1, 2024, including changing the term "importador" to "regularizado por" on labels.

Regulatory Reliance: The AREE Pathway (RDC 741/2022 and IN 290/2024)

One of the most significant recent developments is ANVISA's formal adoption of regulatory reliance mechanisms. In 2022, ANVISA published RDC 741/2022, which established the general criteria for recognizing assessments by Equivalent Foreign Regulatory Authorities (AREE — Autoridade Regulatoria Estrangeira Equivalente).

On April 8, 2024, ANVISA published Normative Instruction IN 290/2024, which operationalized the AREE pathway specifically for medical devices. This reliance route commenced on June 3, 2024 and applies only to Class III and IV medical devices and IVDs subject to the Registro process.

Recognized AREEs and Their Applicable Authorizations

AREE Authority	Country	Accepted Authorization Types
FDA	United States	510(k) Premarket Clearance, Premarket Approval (PMA), De Novo (513(f)(2))
Health Canada	Canada	Medical Device License (MDL)
TGA	Australia	Australian Register of Therapeutic Goods (ARTG) inclusion
MHLW	Japan	Premarket Approval

Notable absence: The EU/EMA is not currently recognized as an AREE for medical devices under IN 290/2024, despite being recognized for pharmaceuticals under IN 289/2024. This means EU CE marking alone cannot be used to leverage the AREE reliance pathway. Manufacturers with EU MDR certifications but no FDA/Health Canada/TGA/MHLW approval cannot use this expedited route.

How the AREE Pathway Works

1. The manufacturer must already hold an authorization from at least one recognized AREE
2. The device submitted to ANVISA must be identical to the device approved by the AREE — same intended use, same indications, same design
3. The device must not have been authorized under an abbreviated procedure by the AREE
4. The manufacturer still submits the complete technical dossier and all documentation required by RDC 751/2022 (or RDC 830/2023 for IVDs), including the Essential Safety and Performance Requirements Checklist per RDC 848/2024
5. The BRH submits supplementary documentation per IN 290/2024 (including the AREE authorization certificate, comparison table, and declaration of conformity)
6. ANVISA conducts its own assessment but relies on the AREE's prior evaluation, which results in significantly faster review times and a reduced likelihood of technical deficiency letters

ANVISA can decline to use the AREE pathway if:

• The supplementary documentation is incomplete or unsatisfactory
• The indications for use differ from those approved by the AREE
• The device has undergone significant design changes since the AREE authorization
• The correlation between the AREE-authorized product and the ANVISA submission cannot be established

Practical tip: The AREE pathway represents a genuine acceleration for manufacturers with FDA clearance/approval. Early experience suggests that Registro applications submitted with AREE documentation receive substantially faster ANVISA review and fewer rounds of technical questions. If you have an FDA 510(k) or PMA, this should be a cornerstone of your Brazil regulatory strategy for Class III/IV devices.

Other Recent Reforms

• RDC 546/2021 — updated adverse event reporting requirements (tecnovigilancia), including specific timelines for reporting deaths, serious injuries, and malfunctions
• RDC 848/2024 — introduced the Essential Safety and Performance Requirements (ESPR) Checklist, required for Registro submissions. Based on the IMDRF document IMDRF/GRRP WG/N47FINAL:2018, this checklist was developed in collaboration with Mercosur jurisdictions.
• RDC 982/2025 (published January 2025) — modernized the GMP/GDP certification framework with a health risk-based model, formally recognizing inspection reports from PIC/S, IMDRF member countries, and MDSAP participants. Expected to further reduce audit redundancy.
• UDI implementation — ANVISA is phasing in Unique Device Identification requirements (RDC 591/2021, amended by RDC 884/2024) on a class-by-class schedule:

Device Class	UDI Compliance Deadline
Class IV	July 2025
Class III	January 2026
Class II	2027
Class I	2028

• Digital health — ANVISA has published RDC 657/2022 specifically for Software as a Medical Device (SaMD) classification and registration, aligned with the IMDRF SaMD framework (IMDRF/SaMD WG/N12FINAL:2014). SaMD is classified independently when standalone.
• COVID-19 legacy provisions — emergency use authorizations and expedited pathways introduced during the pandemic have influenced ANVISA's ongoing approach to fast-tracking innovative devices

In Vitro Diagnostic (IVD) Registration

IVDs follow the same general framework as other medical devices in Brazil — the Cadastro/Registro pathway applies based on risk class — but there are specific requirements and considerations for IVD products.

IVD Classification in Brazil

IVDs in Brazil are classified using a risk-based system that draws on the GHTF/IMDRF IVD classification framework:

Class	Risk Level	Examples
Class I	Low risk	General laboratory instruments, specimen collection containers, general purpose reagents
Class II	Low-moderate risk	Clinical chemistry reagents, hematology analyzers, urine test strips, culture media for non-critical microbiology
Class III	Moderate-high risk	Blood glucose self-testing, companion diagnostics, HLA typing, tumor markers, immunoassays for infectious diseases (non-blood screening)
Class IV	High risk	Blood bank screening (HIV, HBV, HCV), blood grouping reagents (ABO, Rh), NAT testing for blood donations

IVD-Specific Documentation Requirements

In addition to the standard technical documentation, IVDs require:

• Analytical performance data — sensitivity, specificity, accuracy, precision (repeatability, reproducibility), linearity, measuring range, limit of detection, limit of quantitation
• Clinical performance data — diagnostic sensitivity, diagnostic specificity, positive and negative predictive values, clinical agreement studies
• Reference materials and calibrators — traceability to international reference standards where available
• Stability studies — in-use stability, real-time stability, accelerated stability for reagents and controls
• Interfering substances — studies demonstrating the impact (or lack thereof) of common interfering substances
• Sample type validation — validation for each specimen type claimed (serum, plasma, whole blood, urine, etc.)

IVD Reagent Registration vs. Instrument Registration

For IVD systems that include both an instrument (analyzer) and reagents:

• The instrument is registered as a medical device (often Class I or II if it is a general-purpose analyzer)
• Each reagent or test kit is registered separately based on its own risk classification
• System-based registration — ANVISA may accept a system-based approach where the instrument and key reagents are registered together, but individual reagent registrations are still typically required

Practical tip: IVD registration in Brazil often involves managing a large portfolio of reagent registrations, each with its own documentation and renewal timeline. Invest in a regulatory tracking system from the outset. Companies with hundreds of IVD product registrations in Brazil that try to manage renewals and amendments manually inevitably miss deadlines.

Post-Market Requirements

Once your device is registered and on the market in Brazil, ongoing post-market obligations apply. ANVISA takes post-market surveillance seriously, and non-compliance can result in registration suspension or cancellation.

Adverse Event Reporting (Tecnovigilancia)

Brazil's adverse event reporting system is called tecnovigilancia. The BRH is responsible for reporting adverse events to ANVISA through the NOTIVISA system (ANVISA's electronic notification system, transitioning to the new VigiMed platform).

Event Type	Reporting Timeline	Requirements
Death	Immediate (within 24 hours of becoming aware)	Preliminary report within 24 hours; final report within 20 business days
Serious injury	Within 10 business days	Complete report with investigation findings
Malfunction with potential to cause harm	Within 30 business days	Complete report
Trend reporting	As identified	Report when adverse event trends are detected, even if individual events were not reportable

Field Safety Corrective Actions (Recalls)

If a device requires a recall, field safety corrective action, or safety alert, the BRH must:

1. Notify ANVISA immediately
2. Submit a recall plan for ANVISA approval
3. Execute the recall, including direct notification to affected healthcare facilities
4. Submit progress reports to ANVISA
5. Submit a final close-out report

ANVISA publishes recalls on its website and may issue its own safety alerts.

Post-Market Surveillance (PMS)

Manufacturers must maintain a systematic post-market surveillance program that includes:

• Complaint handling — documented process for receiving, investigating, and resolving complaints from the Brazilian market
• Periodic safety update reports — for higher-risk devices, ANVISA may require periodic reports summarizing safety data
• Vigilance trend analysis — ongoing analysis of adverse events, complaints, and field performance
• Literature monitoring — staying current on published literature relevant to the device's safety and performance

Registration Renewal

Registrations must be renewed before expiration. Under RDC 830/2023, the registration validity is 10 years. The renewal application should be submitted at least 6 months before expiration and requires:

• Updated technical documentation (if changes have occurred)
• Summary of post-market surveillance data
• Confirmation that GMP certification remains current
• Payment of renewal fees
• Updated labeling (if applicable)

If you fail to renew before expiration, the registration lapses, and you must submit a new registration — effectively starting over. This is a costly mistake that is easily avoidable with proper regulatory tracking.

Import Requirements

Importing medical devices into Brazil involves several layers of regulatory and customs requirements beyond ANVISA registration.

Prerequisites for Import

• Valid ANVISA registration (Cadastro or Registro) — the device must be registered before it can be imported
• Valid GMP certificate — the manufacturer must hold a current CBPF or MDSAP certificate
• BRH with import authorization — the BRH must hold an AFE (ANVISA operating authorization) that includes import activities, and a valid state-level sanitary license
• Import license (LI — Licenca de Importacao) — must be obtained through the SISCOMEX system (Brazil's integrated foreign trade system) before the shipment arrives in Brazil. ANVISA reviews and authorizes the import license.

Customs and Import Process

1. Import license application — the BRH submits an import license request through SISCOMEX, referencing the ANVISA registration number
2. ANVISA authorization — ANVISA reviews and authorizes the import license (this can take days to weeks)
3. Customs clearance — upon arrival in Brazil, the shipment goes through customs. Customs may inspect the shipment and verify documentation
4. Sanitary inspection — ANVISA or local health surveillance authorities (VISA) may conduct a sanitary inspection at the port of entry
5. Tax and tariff payment — import duties (Imposto de Importacao), IPI (manufactured goods tax), ICMS (state tax), PIS, and COFINS are assessed. Medical devices may benefit from reduced tariff rates under Mercosur agreements or specific tax incentives.

Import Taxes and Duties — A Detailed Breakdown

Medical device import taxes in Brazil are among the most complex in the world. Multiple federal and state taxes are applied in a cascading structure — each tax is calculated on a base that includes previously applied taxes. Understanding this cascade is critical for accurate landed-cost modeling.

The Seven Key Import Taxes and Fees

Tax / Fee	Rate	Calculation Base	Nature
II (Imposto de Importacao) — Import Duty	0% – 16%	CIF value	Federal; rate depends on NCM (Nomenclatura Comum do Mercosul) tariff code
IPI (Imposto sobre Produtos Industrializados)	0% – 15%	CIF + II	Federal; tax on manufactured goods; creditable when product is resold
PIS-Import	2.1%	CIF value	Federal social contribution
COFINS-Import	9.65%	CIF value	Federal social contribution; combined PIS + COFINS = 11.75%
ICMS (Imposto sobre Circulacao de Mercadorias)	17% – 20%	Calculated "por dentro" (see below)	State-level VAT; varies by state; creditable
AFRMM (Adicional ao Frete para Renovacao da Marinha Mercante)	25% of sea freight	Ocean freight value	Federal; applies only to maritime shipments
SISCOMEX fee	R$ 185 (fixed)	Per declaration	Administrative fee for the import declaration system

The ICMS "Por Dentro" Calculation

ICMS is uniquely challenging because it is calculated "por dentro" — the tax itself is included in its own calculation base. The formula is:

ICMS Base = (CIF + II + IPI + PIS + COFINS + customs expenses) / (1 - ICMS rate)

ICMS = ICMS Base x ICMS rate

For example, at an 18% ICMS rate (Sao Paulo):

• If the sum of CIF + all previous taxes + expenses = R$ 100,000
• ICMS Base = R$ 100,000 / (1 - 0.18) = R$ 121,951
• ICMS = R$ 121,951 x 0.18 = R$ 21,951

This "tax on tax" methodology makes ICMS the single largest component of import costs and significantly inflates the effective tax burden beyond what the nominal rate suggests.

ICMS Rates by State

ICMS rates vary by state. The most common rates for imported medical devices are:

State(s)	ICMS Rate
Sao Paulo, Rio de Janeiro, Minas Gerais, Parana and most states	17%
Amapa	18%
Para	19%
Acre, Alagoas, Bahia, Ceara, Paraiba, Piaui, Rio Grande do Norte, Roraima, Sergipe	20%

Note: Some states offer ICMS tax incentives for medical device imports, consisting of total or partial reductions. These incentives change frequently and vary by product category. Your customs broker should identify any applicable state-level incentives.

Worked Example: Total Landed Cost of an Imported Medical Device

Line Item	Value (BRL)
FOB price	R$ 52,000 (USD 10,000 at 5.20 BRL/USD)
Freight	R$ 3,120
Insurance	R$ 260
CIF value	R$ 55,380
II (Import Duty) at 16%	R$ 8,861
IPI at 5% on (CIF + II)	R$ 3,212
PIS-Import at 2.1% on CIF	R$ 1,163
COFINS-Import at 9.65% on CIF	R$ 5,344
AFRMM at 25% of freight	R$ 780
SISCOMEX fee	R$ 185
Customs expenses (est.)	R$ 3,000
Subtotal before ICMS	R$ 77,925
ICMS (18%, calculated "por dentro")	R$ 17,110
Total landed cost	R$ 95,035
Effective increase over FOB	~83%

This example illustrates how a USD 10,000 medical device can cost nearly USD 18,300 by the time it clears Brazilian customs — before any distributor margin, BRH fees, or storage costs.

The Ex-Tarifario Regime

The Ex-Tarifario (ex-tariff) regime is a mechanism that allows temporary reduction of import duty (II) to 0% or 2% for capital goods and IT/telecom equipment that have no equivalent manufactured in Brazil. Some medical devices — particularly capital equipment like imaging systems, surgical robots, or specialized diagnostic equipment — may qualify.

To apply for Ex-Tarifario status:

1. The importer files a petition with the Ministry of Development, Industry, and Foreign Trade (MDIC)
2. MDIC verifies that no equivalent product is manufactured in Brazil
3. If approved, the reduced duty rate applies for a defined period (typically 2 years, renewable)

This can significantly reduce landed costs — eliminating a 16% import duty on a R$ 500,000 piece of equipment saves R$ 80,000.

2026 Tax Reform: CBS and IBS

Brazil is in the process of a major tax reform. Starting January 2026, two new taxes are being introduced in a testing phase:

• CBS (Contribuicao sobre Bens e Servicos) — a federal goods and services contribution replacing PIS/COFINS
• IBS (Imposto sobre Bens e Servicos) — a shared state/municipal tax replacing ICMS and ISS

During the transition period (expected to run through 2032), both the old and new tax systems will coexist. While the immediate financial impact during the testing phase is limited, manufacturers planning long-term market entry should work with Brazilian tax advisors to understand how the reform will affect their cost structure.

Practical tip: Work with a Brazilian customs broker and tax advisor who specializes in medical devices. The intersection of ANVISA regulations, customs requirements, and Brazil's complex tax system creates pitfalls that catch foreign companies off guard. Misclassifying your NCM tariff code, for example, can result in unexpected duties, customs holds, or penalties. A one-digit error in the NCM code can mean the difference between 0% and 16% import duty.

Mercosur Harmonization

Brazil is a founding member of Mercosur (Mercado Comum do Sul / Southern Common Market), a regional trade bloc that also includes Argentina, Paraguay, and Uruguay as full members, with Bolivia as an acceding member and Chile, Colombia, Ecuador, Peru, Suriname, and Guyana as associate members. Mercosur has driven harmonization of medical device regulations among member states since the early 1990s, with more than 120 active harmonized resolutions under the Health Products' Commission.

Key Mercosur Resolutions for Medical Devices

Resolution	Scope	Significance
GMC Resolution No. 25/2021	Medical devices — classification, documentary requirements, registration	Incorporated into Brazil's RDC 751/2022; harmonizes classification rules and documentation requirements across Mercosur
GMC Resolution No. 24/21	IVD medical devices	Incorporated into Brazil's RDC 830/2023; harmonizes IVD regulation across Mercosur
GMC Resolution No. 20/11	GMP requirements for medical devices and IVDs	Basis for Brazil's B-GMP framework; harmonized GMP standards based on ISO 13485
GMC Resolution No. 40	Technical regulation of medical products	Basis for the harmonized Mercosur classification model
Various earlier resolutions	Pre-market authorization, company licensing, inspector training, adverse event information exchange, safety and efficacy requirements	Over 10 resolutions specific to medical devices

Mercosur and B-GMP: Reduced Fees

One of the most tangible benefits of Mercosur membership for manufacturers is reduced B-GMP certification fees. Manufacturers located in Mercosur member countries pay BRL 10,637 (approximately USD 1,980) for B-GMP certification — compared to BRL 72,804.90 (approximately USD 13,500) for manufacturers outside the bloc. This approximately 85% reduction is a significant incentive for manufacturers with production facilities within the Mercosur zone.

Common External Tariff (CET) and Trade Within the Bloc

Mercosur operates a Common External Tariff (CET) — member states apply the same tariff rates on imports from outside the bloc. Medical device tariff codes are classified using the NCM (Nomenclatura Comum do Mercosul) system, which is harmonized across all member states. Within the bloc, medical devices traded between member states may benefit from zero or reduced tariffs under Mercosur's internal trade agreements.

Practical Impact of Mercosur Harmonization

For manufacturers, Mercosur harmonization means:

• Aligned classification — a device classified as Class III in Brazil is likely classified as Class III in Argentina and other Mercosur members, because the classification rules are harmonized under GMC Resolution 25/2021
• Shared GMP framework — GMP certificates recognized by one member state may facilitate recognition by others. ANVISA and its Mercosur counterparts (ANMAT in Argentina, DNVS in Paraguay, MSP in Uruguay) have discussed minimizing duplication of GMP inspections.
• Similar documentation — the technical dossier prepared for Brazil can often be adapted (with translation and local adjustments) for other Mercosur markets. Both RDC 751/2022 and RDC 830/2023 were developed in collaboration with Mercosur jurisdictions, with comments shared among national regulatory authorities.
• Reduced tariff barriers within the bloc — tariff reductions or eliminations for medical devices traded within Mercosur
• Regulatory convergence momentum — Mercosur's alignment with IMDRF standards means that documentation prepared for any IMDRF-aligned jurisdiction (US, EU, Canada, Japan, Australia) is increasingly transferable to the Mercosur region

However, harmonization is not the same as mutual recognition. Each Mercosur member state still conducts its own registration review, and there is no single registration that covers all Mercosur countries. You must register separately in each country — but the aligned requirements make it more efficient to do so.

Free Trade Agreements and Bilateral Cooperation

Beyond Mercosur, Brazil has bilateral trade agreements and Memoranda of Understanding (MOUs) with several countries that can affect medical device trade:

• ANVISA-COFEPRIS (Mexico) MOU — recognizes each other as reference authorities for regulatory reliance; promotes technical cooperation
• Mutual Recognition Agreements (MRAs) — some FTAs include provisions for recognizing testing and certification procedures to reduce redundant testing
• Mercosur FTAs — trade agreements with Israel, Egypt, Palestine, and South Africa may include provisions for streamlined customs procedures and regulatory transparency

Practical tip: If you plan to serve multiple Latin American markets, consider a Mercosur-first strategy. Registering in Brazil (the largest market) first and then adapting your dossier for Argentina, Paraguay, and Uruguay can be highly efficient given the harmonized requirements. Your Brazilian BRH may also have relationships with regulatory agents in other Mercosur countries.

ANVISA vs. FDA vs. EU MDR: A Comparative Overview

Understanding how ANVISA compares to the FDA and EU MDR frameworks helps manufacturers plan a multi-market regulatory strategy.

Feature	ANVISA (Brazil)	FDA (US)	EU MDR (Europe)
Classification system	4 classes (I–IV)	3 classes (I, II, III)	4 classes (I, IIa, IIb, III)
Low-risk pathway	Cadastro (notification)	Class I exempt / 510(k)	Self-declaration (Class I)
Medium-risk pathway	Cadastro (Class II)	510(k)	NB conformity assessment (IIa, IIb)
High-risk pathway	Registro (Classes III/IV)	PMA / De Novo	NB conformity assessment (Class III)
GMP requirement	CBPF or MDSAP certificate	QSR/QMSR (FDA inspection)	ISO 13485 (NB audit under MDR)
In-country representative	BRH (mandatory, holds registration)	US Agent (limited role)	Authorized Representative (EU AR)
Clinical evidence	Required for Classes III/IV; literature-based for I/II	Varies by pathway (510(k) vs. PMA)	Required for all classes (proportionate)
Registration validity	10 years (RDC 830/2023)	Indefinite (510(k)/PMA); annual establishment registration	Certificate validity up to 5 years
Unique Device Identification	Phasing in (aligned with IMDRF)	Mandatory (fully implemented)	Mandatory (phased by class)
Electronic submission	Yes (Solicita system)	Yes (eSTAR for 510(k))	Varies by NB
Post-market surveillance	Tecnovigilancia system	MDR (Medical Device Reporting)	PMS/PMCF per MDR requirements
Regulatory reliance	Considers FDA, Health Canada, EMA, TGA, PMDA decisions	Independent review	Independent review
Language	Portuguese required	English	Official EU language(s) of the member state

Strategic Implications

• FDA-first strategy is common. Many manufacturers obtain FDA clearance/approval first, then use that clinical and technical data as the foundation for their ANVISA dossier. ANVISA's willingness to consider FDA decisions can accelerate the Brazilian review.
• EU MDR data is highly transferable. The clinical evaluation report (CER), risk management file, and technical documentation prepared for EU MDR are closely aligned with what ANVISA expects. Adaptation — rather than recreation — is typically sufficient.
• MDSAP connects the dots. If you already hold an MDSAP certificate for the US and Canada, adding Brazil to your MDSAP scope is a straightforward (though not trivial) expansion that solves the GMP requirement.

Practical Tips for Foreign Manufacturers Entering Brazil

1. Start with GMP — It Is the Longest Lead Item

If you do not already have an MDSAP certificate with Brazil in scope, this is your first priority. Without it, nothing else moves forward. An MDSAP initial certification audit typically requires 6 to 12 months from the decision to pursue it to certificate issuance. If you choose the ANVISA direct inspection route, expect 12 to 24 months.

2. Select Your BRH Early and Carefully

Your BRH is your face to ANVISA and your legal representative in Brazil. A poor choice — whether due to lack of regulatory expertise, inadequate infrastructure, or misaligned incentives — will cost you months and potentially your registration. Due diligence on BRH candidates should include:

• Track record of successful registrations in your device category
• Current ANVISA AFE and state sanitary license status
• Qualified technical director on staff
• Capacity to handle import logistics
• Transparent fee structure
• Clear contract terms regarding registration ownership and transfer rights
• References from current clients

3. Do Not Underestimate Labeling and Translation

Portuguese-language labeling is not a last-step activity. It requires professional medical translation, review by your BRH, and often iterative revision. Start labeling translation in parallel with the technical dossier preparation.

4. Prepare for Deficiency Letters

ANVISA's review process for Registro (Classes III/IV) almost always involves at least one round of deficiency letters (exigencias). This is normal — not a sign that your submission was poor. Budget for at least one to two rounds of deficiency responses in your timeline planning.

5. Leverage Existing Regulatory Approvals — Especially via the AREE Pathway

If you have FDA clearance, EU MDR certification, or approvals from other reference authorities, include these prominently in your ANVISA submission. ANVISA reviewers do consider the regulatory status of a device in other markets, and an existing approval from a trusted authority can positively influence the review.

For Class III and IV devices, the AREE reliance pathway (IN 290/2024) is now your most powerful tool for accelerating Registro timelines. If you hold an FDA 510(k), PMA, or De Novo clearance — or approvals from Health Canada, TGA, or Japan's MHLW — you can formally invoke the reliance route. This does not eliminate the need for a complete technical dossier, but ANVISA's review will leverage the reference authority's prior assessment, resulting in faster approvals and fewer deficiency letters.

6. Plan for the Total Cost of Market Entry

ANVISA fees are only a fraction of the total cost of entering Brazil. Budget for:

• BRH retainer and per-registration fees
• MDSAP audit (if adding Brazil scope) — typically $15,000 to $30,000+ for the incremental scope
• INMETRO certification (if applicable) — $10,000 to $30,000+
• Portuguese translation and labeling design — $5,000 to $20,000+
• Import duties and taxes — 40% to 70% of CIF value
• Customs broker fees
• In-country storage and distribution
• Ongoing post-market surveillance and adverse event reporting costs

7. Understand the Tax Environment

Brazil's tax system is one of the most complex in the world. The effective tax burden on imported medical devices — combining federal import duties, IPI, PIS, COFINS, and state-level ICMS — can dramatically affect your pricing and margin. Engage a Brazilian tax advisor early in your market entry planning.

8. Consider Mercosur Synergies

If you are entering Brazil, consider whether Argentina, Paraguay, or Uruguay are also target markets. The harmonized Mercosur framework means your Brazilian regulatory work can be leveraged for other member states with relatively modest additional effort.

9. Monitor Regulatory Changes

ANVISA's regulatory framework continues to evolve. RDC 830/2023 was a major milestone, but further changes are expected — particularly around UDI implementation, digital health regulation, and post-market surveillance requirements. Your BRH should be monitoring ANVISA's Official Gazette (Diario Oficial da Uniao) and public consultations for relevant developments.

10. Build Relationships with ANVISA

ANVISA is accessible. Pre-submission meetings, while not as formalized as the FDA's Pre-Submission program, are possible and can be valuable for complex or novel devices. Your BRH can facilitate communication with ANVISA reviewers to clarify classification questions, documentation expectations, or clinical evidence requirements before you submit.

Common Pitfalls and How to Avoid Them

Pitfall	Consequence	Prevention
Starting registration without a valid GMP certificate	Application rejected; months of delay	Secure MDSAP certificate with Brazil scope before filing
Choosing a BRH based solely on cost	Poor regulatory execution, missed deadlines, registration issues	Evaluate BRH on experience, capacity, track record, and contract terms
Submitting labeling in English or European Portuguese	Deficiency letter; delay	Use professional Brazilian Portuguese medical translators
Ignoring INMETRO requirements for electromedical equipment	Cannot complete registration for applicable devices	Check INMETRO applicability early and start certification in parallel
Incomplete clinical evidence for Class III/IV	Extended review with multiple deficiency rounds	Prepare a comprehensive clinical evaluation; leverage existing FDA/EU data
Failing to budget for import taxes	Price shock; margin erosion; delayed market entry	Model total landed cost including all applicable Brazilian taxes
Letting registration expire without renewal	Registration lapses; must re-register from scratch	Track renewal deadlines; submit renewal at least 6 months before expiration
Not responding to deficiency letters within the deadline	Application may be archived (denied)	Monitor ANVISA correspondence closely; respond within required timelines
Neglecting post-market surveillance	ANVISA enforcement action; potential registration suspension	Implement tecnovigilancia procedures from day one
Not leveraging AREE pathway for Class III/IV with existing FDA/HC/TGA/MHLW approval	Missing opportunity for significantly faster Registro review	Submit AREE supplementary documentation per IN 290/2024 alongside the Registro application
Forgetting ANATEL certification for wireless devices	Registration blocked; ANVISA requires ANATEL homologation ID before approval	Check if device uses Bluetooth, Wi-Fi, RF, or cellular; start ANATEL process in parallel
Using 2-year B-GMP budget when MDSAP qualifies for 4-year extension	Overpaying by ~50% on B-GMP certification costs over time	Confirm MDSAP includes Brazil in scope; new/renewed B-GMP certificates automatically get 4-year validity per RDC 850/2024
Not modeling the full cascading import tax structure	Underpriced products; margin erosion; surprise costs at customs	Model CIF + II + IPI + PIS + COFINS + ICMS ("por dentro") + AFRMM for total landed cost
Choosing a BRH without verifying AFE scope	BRH may not be authorized for import activities	Verify BRH's AFE explicitly covers import, distribution, and storage activities

Conclusion

Brazil is a large, growing, and strategically important medical device market. But it demands deliberate regulatory planning. The combination of ANVISA registration, GMP certification (best addressed through MDSAP), INMETRO certification for electromedical and other specified equipment, ANATEL certification for wireless devices, the BRH requirement, Portuguese labeling, and Brazil's complex tax environment means that market entry requires sustained commitment and resources.

The regulatory framework has improved significantly with the modernization wave of 2022-2024 — RDC 751/2022 consolidated and aligned medical device classification with EU MDR rules, RDC 830/2023 did the same for IVDs, RDC 850/2024 extended B-GMP validity to four years for MDSAP-certified manufacturers, and IN 290/2024 introduced the AREE regulatory reliance pathway that can dramatically accelerate Registro timelines for manufacturers with FDA, Health Canada, TGA, or MHLW approvals. Registration validity has doubled to 10 years, documentation requirements are better aligned with international standards, and ANVISA's formal reliance mechanisms create real opportunities for manufacturers with existing approvals from reference authorities.

The manufacturers who succeed in Brazil are those who start early (especially on GMP and MDSAP), choose their BRH wisely, invest in proper documentation and translation, understand the true landed cost of their products (including the cascading import tax structure), and treat Brazil as a market that deserves dedicated regulatory attention rather than an afterthought to their US or EU strategy.